| __timestamp | Amphastar Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 179279000 |
| Thursday, January 1, 2015 | 174172000 | 186359000 |
| Friday, January 1, 2016 | 150976000 | 171785000 |
| Sunday, January 1, 2017 | 149380000 | 208136000 |
| Monday, January 1, 2018 | 187681000 | 198405000 |
| Tuesday, January 1, 2019 | 190434000 | 224169000 |
| Wednesday, January 1, 2020 | 206506000 | 245044000 |
| Friday, January 1, 2021 | 238029000 | 252314000 |
| Saturday, January 1, 2022 | 250127000 | 268225000 |
| Sunday, January 1, 2023 | 293274000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, Amphastar Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have been pivotal players. From 2014 to 2023, Taro consistently outpaced Amphastar in cost of revenue, with a notable 7% higher average. In 2023, Taro's cost of revenue peaked at approximately 3.05 billion, marking a 70% increase from 2014. Amphastar, while trailing, showed a robust growth of 84% over the same period, reaching around 2.93 billion in 2023. This upward trend reflects the companies' strategic investments in production and distribution. However, 2024 data for Amphastar remains elusive, leaving room for speculation on its future trajectory. As these companies continue to innovate, their financial strategies will be crucial in maintaining their market positions.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Amgen Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored